Prospective and Retrospective Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia (Acute Leukemia HSCT Cohort)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02344953|
Recruitment Status : Recruiting
First Posted : January 26, 2015
Last Update Posted : March 18, 2019
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||January 2021|
- Overall survival [ Time Frame: 10years ]Overall survival (OS) is defined as the time from date of diagnosis until death due to any cause within the follow-up period. Surviving patients are censored at date of last contact.
- Progression-free survival [ Time Frame: 10years ]Progression-free survival (PFS) is defined as survival without disease progression or relapse; patients alive without disease progression or relapse are censored on the last assessment date. Median OS and PFS are calculated using Kaplan-Meier estimates with a 95% confidence interval.
- Treatment-related mortality [ Time Frame: 10years ]Treatment-related mortality was defined as death unrelated to refractory or progressive disease occurring before first remission was achieved, or any death in complete remission
- Complete remission rate [ Time Frame: 10 years ]Response assessment is performed according to the criteria reported by BD Cheson et al. (Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02344953
|Contact: JUNE-WON CHEONG, MD||82-2-2228-1970||JWCHONG70@yuhs.ac|
|Korea, Republic of|
|Yonsei University College of Medicine||Recruiting|
|Seoul, Korea, Republic of, 120-752|
|Contact: JUNE-WON CHEONG, MD 82-2-2228-1970 JWCHONG70@yuhs.ac|